
This #WorldDiabetesDay, we're highlighting the importance of early action on diabetes. Learn more about our work in diabetes care here: spkl.io/60127bTHA #WorldDiabetesDay #Diabetes #WDD2026 #ActEarlyOnDiabetes
✓An R&D driven, AI-powered biopharma company committed to improving lives and delivering compelling growth. Terms for interactions: bit.ly/sanofi-terms

This #WorldDiabetesDay, we're highlighting the importance of early action on diabetes. Learn more about our work in diabetes care here: spkl.io/60127bTHA #WorldDiabetesDay #Diabetes #WDD2026 #ActEarlyOnDiabetes

Our Q3 2026 results are now available. Read the full press release for detailed insights: spkl.io/60137ZJ1J #SanofiResults $SAN $SNY

Following our acquisition of Blueprint Medicines, we're uniting our teams, knowledge, and capabilities to improve the lives of people with systemic mastocytosis. Read the full letter from Maria Roche: spkl.io/60137kl4S

#NEWS: Positive phase 2b long-term data in ulcerative colitis and Crohn's disease, shared at UEG Week. Read more: sanofi.com/en/media-room/pre… @Teva #UEGWeek2026

NEWS: We’ve officially started construction on our new state-of-the-art insulin production facility. It will strengthen our ability to reliably supply insulin to millions of people living with #diabetes in Europe and worldwide. Read more here: spkl.io/60117XjmU

We're proud to announce our major partnership with @LeTour de France and @LeTourFemmes as the official sponsor of the white jersey for the best young rider. For both men's and women's categories, the white jersey represents progress, a value at the heart of Sanofi's quest for innovation. The #RaceForHealth Is On! 🚴♂️🚴♀️ #TDF2027 #SanofiTDF #TourDeFrance


#NEWS: We’ve announced an expansion of our global Alliance with @Regeneron to add multiple next-generation, long-acting antibodies to our joint immunology portfolio. Read more here: spkl.io/60177pWkN

Our Q2 2026 results are now available. Read the full press release for detailed insights: spkl.io/60197KQtR #SanofiResults $SAN $SNY

#NEWS: Update on our phase 3 program in moderate-to-severe #AtopicDermatitis. Learn more ⬇️ spkl.io/60127JNVK

#NEWS: Our phase 3 results show our medicine met its primary and secondary endpoints in treatment-naïve infants with infantile-onset Pompe disease (IOPD). Read more: sanofi.com/en/media-room/pre…

#NEWS: The Japan Ministry of Health, Labour and Welfare has approved the first oral, reversible BTK inhibitor to treat adults with immune thrombocytopenia (ITP) who are refractory to other treatments. Read more ⬇️: sanofi.com/en/media-room/pre…

#NEWS: The @EU_Commission has approved our medicine for the treatment of certain people with secondary progressive #MultipleSclerosis , reinforcing our commitment to advancing scientific innovation that address unmet patient needs. Learn more ⬇️ sanofi.com/en/media-room/pre…

Sanofi appoints Paulo Fontoura as Global Head of R&D Pharma, starting September 1, 2026. With 25+ years in pharmaceutical innovation, he brings a track record of 60+ new molecular entities and 20+ FDA/EMA approvals. Read more: sanofi.com/en/media-room/pre… #Sanofi

We're chasing the miracles of science to improve people's lives. Last week, the world saw exactly how. 2026 marked our 8th consecutive year at #VivaTech, and we came to show, not tell, with operational AI delivering real impact for patients, today. Learn more: spkl.io/60157EwPB
